Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis

shire
Shire hooks up with Microsoft and Eurordis to create a global commission intent on improving time to diagnosis in rare diseases. (Shire)

Slow diagnosis is all too common in the rare disease world, and Shire has forged a new partnership with Microsoft aimed at changing that. Along with patient organization alliance Eurordis, they've created a global "commission" to accelerate diagnosis and treatment.

The trio's new effort—bearing an official-sounding name, the Global Commission to End the Diagnostic Odyssey for Children—will develop “an actionable roadmap” for removing barriers to rare disease diagnosis.

The idea was born in 2017 when Shire was investigating how to break down barriers in rare disease diagnosis, CEO Flemming Ornskov said in an email interview.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We considered how the convergence of healthcare and technology was already helping Shire drive solutions for patients. We realized we could combine our momentum with Microsoft’s previous success to develop innovative approaches to accelerate time to diagnosis,” said Ornskov, who's also co-chair of the commission.

The goals? Improve doctors’ ability to identify and diagnose patients, give patients and families a more active role, and offer high-level policy guidance. The commission is focused on children because more than half of rare diseases are pediatric disorders. The group plans to publish its work in early 2019.

One of the biggest problems for patients and their caregivers is the "diagnostic odyssey," Ornskov said, and that journey to an accurate diagnosis lasts an average of five years or more. “Patients are born and living with rare diseases every day, so the sooner the Global Commission can deliver this actionable roadmap, the sooner patients and those caring for them will be able to better handle this devastating problem," he said.

RELATED: Sanofi, Shire, Vertex and more back first-ever rare disease film festival

Adding the patient voice with Eurordis was important he said, to create a cross-functional, global group that can speed results through diverse perspectives and experiences.

Shire’s focus on rare disease, which now accounts for 70% of its revenues, includes many other technology initiatives such as investments in gene therapy and tailoring treatments, and working with small digital incubators as well as tech giants to develop patient-support solutions.

“Whether large or small, all of our partnerships fuel our mission to create a digitized Shire that supports patients through every step of their journey,” Ornskov said.

RELATED: Shire divvies up its operations to prime neuroscience unit for future sale or spinoff

Other efforts in rare disease patient support include Shire’s three-year, $5 million Future Generation program begun in 2016. It has several components, including a partnership with the Paul Newman-founded SeriousFun Children's Network of camps for children with rare diseases, and on the research side, addresses the shortage of medical geneticists by giving grants through the American College for Medical Genetics and Genomics Foundation.

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.